Supernus Pharmaceuticals, Inc.
Market Cap
$2.93B
P/E Ratio
-74.74
EPS
$-0.68
Dividend Yield
0.00%
52-Week Range
$29.16 — $59.68
Volume
525.46K
Avg Volume
747.46K
Beta
0.72
P/E (TTM)
-74.74
Forward P/E
16.66
PEG Ratio
0.75
P/S (TTM)
4.29
P/B (TTM)
0.00
P/FCF
-43.62
EV/EBITDA
-70.37x
EV/Sales
—
ROE (TTM)
-0.00%
ROA (TTM)
-0.00%
ROIC
-0.06%
Gross Margin
0.86%
Operating Margin
-0.06%
Net Margin
-0.23%
Debt/Equity
0.03
Current Ratio
1.90
EPS Growth (YoY)
-2.15%
Revenue Growth (YoY)
+0.07%
EPS Growth (3Y)
+17.91%
EPS Growth (5Y)
+10.66%
Sales Growth (3Y)
+0.05%
Sales Growth (5Y)
+0.12%
EPS Est (This Year)
$3.05
EPS Est (Next Year)
$3.46
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$5382.78
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $61.00(20.0% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
-20710
Outstanding Shares
57.34M
Float
54.42M
Free Float %
94.90%
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
NASDAQ
IPO Date
2012-05-01
Employees
674
CEO
Jack A. Khattar
Index Membership
—
Website
https://www.supernus.com
Supernus Pharmaceuticals, Inc. (SUPN) is a healthcare company in the drug manufacturers - specialty & generic industry listed on the NASDAQ. With a market capitalization of $2.93B, a P/E ratio of -74.74, SUPN is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare SUPN against other stocks using dozens of fundamental and technical filters.
Supernus Pharmaceuticals, Inc. (SUPN) has a trailing twelve-month (TTM) P/E ratio of -74.74. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Supernus Pharmaceuticals, Inc. (SUPN) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Supernus Pharmaceuticals, Inc. (SUPN) has a market capitalization of $2.93 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on Supernus Pharmaceuticals, Inc. (SUPN) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $61.00 implies 20.0% upside from the current price.